Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Group B Streptococcus alpha-like protein N-terminal domain is a highly conserved N-terminal region of a family of surface proteins (including Alpha C, Rib, Alp1, Alp2, Alp3) present on Group B Streptococcus (GBS). This domain is structurally unique, consisting of a beta-sandwich and three-helix bundle, with similarities to type III fibronectin folds. It mediates GBS binding and internalization into human epithelial cells, acts as an invasin, and is key for virulence. The N-terminal domain contains motifs that bind to host integrins and heparin, supporting adhesion and translocation across epithelial barriers. Antibodies against these domains are highly immunogenic, block cell entry, and protect against infection, making this domain a promising candidate for GBS maternal vaccines to prevent neonatal disease[1][2][4][5].
Blockade by antibodies or soluble N-terminal domain fragments inhibits internalization and invasion of GBS into host epithelial cells[1][5] Antibodies mediate opsonophagocytic killing of GBS[5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Group B Streptococcus alpha-like protein N-terminal domain.